RhumbLine Advisers
RANI icon

RhumbLine Advisers’s Rani Therapeutics RANI Stock Holding History

RhumbLine Advisers’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-312
Closed -$1.19K – 4307
2024
Q2 		$1.19K Hold
312
– – ﹤0.01% 4228
2024
Q1 		$970 Hold
312
– – ﹤0.01% 4148
2023
Q4 		$1.03K Hold
312
– – ﹤0.01% 4150
2023
Q3 		$678 Hold
312
– – ﹤0.01% 4212
2023
Q2 		$1.28K Buy
+312
New +$1.45K ﹤0.01% 4262

Other funds holding RANI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

RhumbLine Advisers's RANI Position: Q3 2024 in Review

RhumbLine Advisers sold out of Rani Therapeutics (RANI) in Q3 2024, closing a stake of 312 shares — an estimated $1.19K sold.

RhumbLine Advisers first reported a position in RANI in Q2 2023 and held it in 5 quarters. The position peaked at $1.28K in Q2 2023. 31 funds tracked by Wall St. Rank hold RANI as of Q3 2024.

  • RhumbLine Advisers reported no remaining Rani Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 312 Rani Therapeutics shares in Q3 2024, an estimated $1.19K.
  • RhumbLine Advisers first reported a position in Rani Therapeutics in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's Rani Therapeutics position peaked at $1.28K in Q2 2023.
  • 31 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.